Morgan Stanley assumed coverage of Integra LifeSciences (IART) with an Underweight rating with a price target of $20, down from $25. The firm maintains concerns regarding the company’s execution against its topline growth and margin expansion initiatives, calling it a “show-me” story.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IART:
- Integra LifeSciences price target raised to $26 from $21 at Truist
- Integra LifeSciences price target raised to $22 from $16 at Citi
- Integra LifeSciences Announces Q3 2024 Financial Results
- Nvidia to replace Intel on DJIA, Berkshire reports Q3 results: Morning Buzz
- Morning Movers: Air Transport Services jumps following $3.1B take-private deal